

Haematologica
HAEMATOL/2018/189514
Version 3

The addition of the mTORr inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCR1 AML17 trial

Alan K Burnett, Emma Das Gupta, Steve Knapper, Asim Khwaja, Marion Sweeney, Lars Kjeldsen, Timothy Hawkins, Sophie E. Betteridge, Paul Cahalin, Richard E. Clark, Robert K. Hills, and Nigel H. Russell

Disclosures: The authors are grateful to Novartis for the provision of everolimus, to Cancer Research UK for research funding of the trial and to the investigators, research staff and patients in the participating sites. No authors report relevant conflicts of interest.

Contributions: AKB was co-Chief Investigator; devised the study; wrote the manuscript. EDG co-ordinated the study and wrote the manuscript. AK, LK, LP, PC, REC were highest recruiting investigators. SK and MS developed the PIA assay. RKH undertook the Statistical and data supervision and analysed the data. NHR was co-Chief Investigator. All authors reviewed the manuscript.